IL5 and inflammatory bowel disease: A previous study utilizing dextran sulfate sodium (DSS) -induced colitis models demonstrated that IL-5 antagonists effectively inhibit IL-5/IL-5RA signaling pathway, leading to the suppression of STAT5 activity and reductions in IL-1β and caspase-1 levels (36), contributing to the development of IBD by promoting intestinal inflammation and tissue damage (37).